Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: A prospective observational study

Ahmad Al Rifai; Neeraj Prasad; Elinor Shuttleworth; Helen McBurney; Sudeep Pushpakom; Andrew Robinson; William Newman; Simon Campbell

doi:10.1097/MEG.0b013e32834233a2

Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: A prospective observational study

Ahmad Al Rifai, Neeraj Prasad, Elinor Shuttleworth, Helen McBurney, Sudeep Pushpakom, Andrew Robinson, William Newman, Simon Campbell

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Azathioprine (AZA) is commonly used in inflammatory bowel disease (IBD) patients. Lymphopenia is a recognized effect of this treatment, but lymphopenia-related complications in IBD patients have not been widely reported. The incidence and progression of AZA-induced lymphopenia in IBD patients is not well described. There is no consensus on its optimal management in this group. AIMS AND Methods: We assessed the incidence and progression of lymphopenia and its related complications in a cohort of IBD patients over a 14-month period in two large tertiary gastroenterology units. Analysis of prospectively collected data was performed. Results: Fifty-two patients were studied prospectively with a median age of 34 years. Eighteen patients (34.6%) developed lymphopenia (

Original language	English
Pages (from-to)	153-158
Number of pages	5
Journal	European Journal of Gastroenterology and Hepatology
Volume	23
Issue number	2
DOIs	https://doi.org/10.1097/MEG.0b013e32834233a2
Publication status	Published - Feb 2011

Keywords

azathioprine
Crohn's disease
glutathione-S-transferase M1
inflammatory bowel disease
leucopenia
lymphopenia
neutropenia
opportunistic infections
thiopurines
ulcerative colitis

Access to Document

10.1097/MEG.0b013e32834233a2

Cite this

@article{db3d1b4ebace4dad80def4b1fe12d41b,

title = "Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: A prospective observational study",

abstract = "Introduction: Azathioprine (AZA) is commonly used in inflammatory bowel disease (IBD) patients. Lymphopenia is a recognized effect of this treatment, but lymphopenia-related complications in IBD patients have not been widely reported. The incidence and progression of AZA-induced lymphopenia in IBD patients is not well described. There is no consensus on its optimal management in this group. AIMS AND Methods: We assessed the incidence and progression of lymphopenia and its related complications in a cohort of IBD patients over a 14-month period in two large tertiary gastroenterology units. Analysis of prospectively collected data was performed. Results: Fifty-two patients were studied prospectively with a median age of 34 years. Eighteen patients (34.6%) developed lymphopenia (",

keywords = "azathioprine, Crohn's disease, glutathione-S-transferase M1, inflammatory bowel disease, leucopenia, lymphopenia, neutropenia, opportunistic infections, thiopurines, ulcerative colitis",

author = "Rifai, {Ahmad Al} and Neeraj Prasad and Elinor Shuttleworth and Helen McBurney and Sudeep Pushpakom and Andrew Robinson and William Newman and Simon Campbell",

year = "2011",

month = feb,

doi = "10.1097/MEG.0b013e32834233a2",

language = "English",

volume = "23",

pages = "153--158",

journal = "European Journal of Gastroenterology and Hepatology",

issn = "1473-5687",

publisher = "Lippincott Williams & Wilkins",

number = "2",

}

TY - JOUR

T1 - Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: A prospective observational study

AU - Rifai, Ahmad Al

AU - Prasad, Neeraj

AU - Shuttleworth, Elinor

AU - McBurney, Helen

AU - Pushpakom, Sudeep

AU - Robinson, Andrew

AU - Newman, William

AU - Campbell, Simon

PY - 2011/2

Y1 - 2011/2

N2 - Introduction: Azathioprine (AZA) is commonly used in inflammatory bowel disease (IBD) patients. Lymphopenia is a recognized effect of this treatment, but lymphopenia-related complications in IBD patients have not been widely reported. The incidence and progression of AZA-induced lymphopenia in IBD patients is not well described. There is no consensus on its optimal management in this group. AIMS AND Methods: We assessed the incidence and progression of lymphopenia and its related complications in a cohort of IBD patients over a 14-month period in two large tertiary gastroenterology units. Analysis of prospectively collected data was performed. Results: Fifty-two patients were studied prospectively with a median age of 34 years. Eighteen patients (34.6%) developed lymphopenia (

AB - Introduction: Azathioprine (AZA) is commonly used in inflammatory bowel disease (IBD) patients. Lymphopenia is a recognized effect of this treatment, but lymphopenia-related complications in IBD patients have not been widely reported. The incidence and progression of AZA-induced lymphopenia in IBD patients is not well described. There is no consensus on its optimal management in this group. AIMS AND Methods: We assessed the incidence and progression of lymphopenia and its related complications in a cohort of IBD patients over a 14-month period in two large tertiary gastroenterology units. Analysis of prospectively collected data was performed. Results: Fifty-two patients were studied prospectively with a median age of 34 years. Eighteen patients (34.6%) developed lymphopenia (

KW - azathioprine

KW - Crohn's disease

KW - glutathione-S-transferase M1

KW - inflammatory bowel disease

KW - leucopenia

KW - lymphopenia

KW - neutropenia

KW - opportunistic infections

KW - thiopurines

KW - ulcerative colitis

U2 - 10.1097/MEG.0b013e32834233a2

DO - 10.1097/MEG.0b013e32834233a2

M3 - Article

C2 - 21164349

SN - 1473-5687

VL - 23

SP - 153

EP - 158

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

IS - 2

ER -

Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: A prospective observational study

Abstract

Keywords

Access to Document

Fingerprint

Cite this